Both in Biotechnology
Intensity Therapeutics vs Acumen Pharmaceuticals
Over the past year INTS returned −78.2% and ABOS returned −89.5%; their daily moves had a correlation of 0.00.
INTS −78.2% ABOS −89.5%Growth of $1, one year, split-adjusted
| Metric | INTS | ABOS |
|---|---|---|
| Price | $3.10 | $0.2138 |
| Market cap | $10.1M | $15.5M |
| Today | −11.43% | −1.16% |
| 1 month | −18.4% | −89.8% |
| 6 months | −39.3% | −91.3% |
| Year to date | −69.8% | −89.9% |
| 1 year | −76.8% | −89.0% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $9.5M | $52.3M |
| Dividend yield | — | — |
| Volatility (60d) | 67.0% | 492.8% |
| Short % of float | 2.9% | 7.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).